Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate
Portfolio Pulse from
Ratio Therapeutics Inc. has entered into a license and collaboration agreement with Novartis Pharma AG to develop a radiotherapeutic candidate targeting Somatostatin Receptor 2 (SSTR2) for cancer treatment. Ratio will receive upfront payments, potential milestones, and tiered royalties.
November 18, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novartis has entered a collaboration with Ratio Therapeutics to develop a radiotherapeutic candidate targeting SSTR2, which could enhance its oncology portfolio.
The collaboration with Ratio Therapeutics could strengthen Novartis's oncology offerings, potentially leading to future revenue from the developed radiotherapeutic. The upfront and milestone payments indicate a significant investment in this partnership.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80